Bioorganic & Medicinal Chemistry 2007-01-01

Synthesis and biological evaluation of imidazo[1,2-a]pyridine derivatives as novel PI3 kinase p110alpha inhibitors.

Masahiko Hayakawa, Hiroyuki Kaizawa, Ken-Ichi Kawaguchi, Noriko Ishikawa, Tomonobu Koizumi, Takahide Ohishi, Mayumi Yamano, Minoru Okada, Mitsuaki Ohta, Shin-Ichi Tsukamoto, Florence I Raynaud, Michael D Waterfield, Peter Parker, Paul Workman

Index: Bioorg. Med. Chem. 15(1) , 403-12, (2007)

Full Text: HTML

Abstract

3-{1-[(4-Fluorophenyl)sulfonyl]-1H-pyrazol-3-yl}-2-methylimidazo[1,2-a]pyridine, 2a, was discovered in our chemical library as a novel p110alpha inhibitor with an IC(50) of 0.67microM, through screening in a scintillation proximity assay. Optimization of the substituents of 2a increased the p110alpha inhibitory activity by more than 300-fold (2g: IC(50)=0.0018microM). Further structural modification of 2g afforded thiazole derivative 12, which has potent p110alpha inhibitory activity (IC(50) of 0.0028microM) and is highly selective for p110alpha over other PI3K isoforms. Compound 12 also inhibited serum-induced cell proliferation of A375 and HeLa cells in vitro with IC(50) values of 0.14microM and 0.21microM, respectively, and suppressed tumor growth by 37% in a mouse HeLa xenograft model when dosed intraperitoneally at 25mg/kg. These results suggest that selective p110alpha inhibitors may have potential as cancer therapeutic agents.